Adam Michael Maley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Michael Maley has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- David R. Walt
Wyss Institute for Biologically Inspired Engineering, Boston, USA
5 shared publications - Robert M. Corn
Department of Chemistry, University of California-Irvine, Irvine, California 92697, United States
5 shared publications Connie Wu
Department of Pathology, Brigham and Women’s Hospital, Boston, MA
3 shared publicationsTal Gilboa
Department of Pathology, Brigham and Women’s Hospital, Boston, MA
3 shared publicationsAlana F. Ogata
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
2 shared publicationsChih-Ping Mao
Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2 shared publications
Latest Publications
- Open Access
- 1 November 2021
- Published by American Chemical Society (ACS) in ACS Nanoscience Au
- Vol. 1 (1) , 6-14
The Primarily Undergraduate Nanomaterials Cooperative: A New Model for Supporting Collaborative Research at Small Institutions on a National Scale
- 1 November 2021
- Published by American Chemical Society (ACS) in ACS Nanoscience Au
- Vol. 1 (1) , 6-14
Open AccessThe Primarily Undergraduate Nanomaterials Cooperative: A New Model for Supporting Collaborative Research at Small Institutions on a National Scale
- 30 November 2020
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 66 (12) , 1562-1572
Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 21 million people worldwide since August 16, 2020. Compared to PCR and serology tests, SARS-CoV-2 antigen assays are underdeveloped, despite their potential to identify active infection and monitor disease progression. Methods: We used Single Molecule Array (Simoa) assays to quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of patients with coronavirus disease (COVID-19). We studied plasma from 64 patients who were COVID-19 positive, 17 who were COVID-19 negative, and 34 prepandemic patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we quantified changes in 31 SARS-CoV-2 biomarkers in 272 longitudinal plasma samples obtained for 39 patients with COVID-19. Data were analyzed by hierarchical clustering and were compared to longitudinal RT-PCR test results and clinical outcomes. Results: SARS-CoV-2 S1 and N antigens were detectable in 41 out of 64 COVID-19 positive patients. In these patients, full antigen clearance in plasma was observed a mean ± 95% CI of 5 ± 1 days after seroconversion and nasopharyngeal RT-PCR tests reported positive results for 15 ± 5 days after viral-antigen clearance. Correlation between patients with high concentrations of S1 antigen and ICU admission (77%) and time to intubation (within 1 day) was statistically significant. Conclusions: The reported SARS-CoV-2 Simoa antigen assay is the first to detect viral antigens in the plasma of patients who were COVID-19 positive to date. These data show that SARS-CoV-2 viral antigens in the blood are associated with disease progression, such as respiratory failure, in COVID-19 cases with severe disease.
- 30 November 2020
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 66 (12) , 1562-1572
Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 21 million people worldwide since August 16, 2020. Compared to PCR and serology tests, SARS-CoV-2 antigen assays are underdeveloped, despite their potential to identify active infection and monitor disease progression. Methods: We used Single Molecule Array (Simoa) assays to quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of patients with coronavirus disease (COVID-19). We studied plasma from 64 patients who were COVID-19 positive, 17 who were COVID-19 negative, and 34 prepandemic patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we quantified changes in 31 SARS-CoV-2 biomarkers in 272 longitudinal plasma samples obtained for 39 patients with COVID-19. Data were analyzed by hierarchical clustering and were compared to longitudinal RT-PCR test results and clinical outcomes. Results: SARS-CoV-2 S1 and N antigens were detectable in 41 out of 64 COVID-19 positive patients. In these patients, full antigen clearance in plasma was observed a mean ± 95% CI of 5 ± 1 days after seroconversion and nasopharyngeal RT-PCR tests reported positive results for 15 ± 5 days after viral-antigen clearance. Correlation between patients with high concentrations of S1 antigen and ICU admission (77%) and time to intubation (within 1 day) was statistically significant. Conclusions: The reported SARS-CoV-2 Simoa antigen assay is the first to detect viral antigens in the plasma of patients who were COVID-19 positive to date. These data show that SARS-CoV-2 viral antigens in the blood are associated with disease progression, such as respiratory failure, in COVID-19 cases with severe disease.
- 28 September 2020
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 5 (10) , 3037-3042
Simplified Digital Enzyme-Linked Immunosorbent Assay Using Tyramide Signal Amplification and Fibrin Hydrogels
Many protein biomarkers occur at very low concentrations in biofluids like blood and saliva and ultra-sensitive detection methods are required in order to measure them. Approaches such as digital enzyme-linked immunosorbent assays (ELISA) and single molecule arrays (Simoa) have been developed to accurately quantitate protein concentrations as low as attomolar levels. Although these techniques are being implemented in research and clinical laboratories to develop ultra-sensitive clinical diagnostic assays, the size and cost of the instruments required to run these digital assays have precluded them from being implemented into point-of-care diagnostic formats. Here, we report the development of a simplified digital ELISA format that is more amenable to point-of-care technologies, referred to as Catalyzed Reporter Deposition digital ELISA (CARD-dELISA). On-bead signal generation using the CARD tyramide signal amplification technique is combined with bead immobilization in fibrin hydrogels for single molecule counting in a simplified workflow format. CARD-dELISA allows for ultra-sensitive protein detection (IL-6: ~1 fM) with a dynamic range similar to the conventional Simoa assay. We use CARD-dELISA to measure IL-6 in saliva samples and show good agreement with conventional Simoa.
- 28 September 2020
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 5 (10) , 3037-3042
Simplified Digital Enzyme-Linked Immunosorbent Assay Using Tyramide Signal Amplification and Fibrin Hydrogels
Many protein biomarkers occur at very low concentrations in biofluids like blood and saliva and ultra-sensitive detection methods are required in order to measure them. Approaches such as digital enzyme-linked immunosorbent assays (ELISA) and single molecule arrays (Simoa) have been developed to accurately quantitate protein concentrations as low as attomolar levels. Although these techniques are being implemented in research and clinical laboratories to develop ultra-sensitive clinical diagnostic assays, the size and cost of the instruments required to run these digital assays have precluded them from being implemented into point-of-care diagnostic formats. Here, we report the development of a simplified digital ELISA format that is more amenable to point-of-care technologies, referred to as Catalyzed Reporter Deposition digital ELISA (CARD-dELISA). On-bead signal generation using the CARD tyramide signal amplification technique is combined with bead immobilization in fibrin hydrogels for single molecule counting in a simplified workflow format. CARD-dELISA allows for ultra-sensitive protein detection (IL-6: ~1 fM) with a dynamic range similar to the conventional Simoa assay. We use CARD-dELISA to measure IL-6 in saliva samples and show good agreement with conventional Simoa.
- 18 September 2020
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 4 (12) , 1180-1187
Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19
Sensitive assays are essential for the accurate identification of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report a multiplexed assay for the fluorescence-based detection of seroconversion in infected individuals from less than 1 µl of blood, and as early as the day of the first positive nucleic acid test after symptom onset. The assay uses dye-encoded antigen-coated beads to quantify the levels of immunoglobulin G (IgG), IgM and IgA antibodies against four SARS-CoV-2 antigens. A logistic regression model trained using samples collected during the pandemic and samples collected from healthy individuals and patients with respiratory infections before the first outbreak of coronavirus disease 2019 (COVID-19) was 99% accurate in the detection of seroconversion in a blinded validation cohort of samples collected before the pandemic and from patients with COVID-19 five or more days after a positive nasopharyngeal test by PCR with reverse transcription. The high-throughput serological profiling of patients with COVID-19 allows for the interrogation of interactions between antibody isotypes and viral proteins, and should help us to understand the heterogeneity of clinical presentations.
- 18 September 2020
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 4 (12) , 1180-1187
Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19
Sensitive assays are essential for the accurate identification of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report a multiplexed assay for the fluorescence-based detection of seroconversion in infected individuals from less than 1 µl of blood, and as early as the day of the first positive nucleic acid test after symptom onset. The assay uses dye-encoded antigen-coated beads to quantify the levels of immunoglobulin G (IgG), IgM and IgA antibodies against four SARS-CoV-2 antigens. A logistic regression model trained using samples collected during the pandemic and samples collected from healthy individuals and patients with respiratory infections before the first outbreak of coronavirus disease 2019 (COVID-19) was 99% accurate in the detection of seroconversion in a blinded validation cohort of samples collected before the pandemic and from patients with COVID-19 five or more days after a positive nasopharyngeal test by PCR with reverse transcription. The high-throughput serological profiling of patients with COVID-19 allows for the interrogation of interactions between antibody isotypes and viral proteins, and should help us to understand the heterogeneity of clinical presentations.
- Open Access
- 6 September 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (4) , e2001111
Sequential Protein Capture in Multiplex Single Molecule Arrays: A Strategy for Eliminating Assay Cross‐Reactivity
Measurements of multiple biomolecules within the same biological sample are important for many clinical applications to enable accurate disease diagnosis or classification. These disease‐related biomarkers often exist at very low levels in biological fluids, necessitating ultrasensitive measurement methods. Single‐molecule arrays (Simoa), a bead‐based digital enzyme‐linked immunosorbent assay, is the current state of the art for ultrasensitive protein detection and can detect sub‐femtomolar protein concentrations, but its ability to achieve high‐order multiplexing without cross‐reactivity remains a challenge. Here, a sequential protein capture approach for multiplex Simoa assays is implemented to eliminate cross‐reactivity between binding reagents by sequentially capturing each protein analyte and then incubating each capture bead with only its corresponding detection antibody. This strategy not only reduces cross‐reactivity to background levels and significantly improves measurement accuracies, but also enables higher‐order multiplexing. As a proof of concept, the sequential multiplex Simoa assay is used to measure five different cytokines in plasma samples from Coronavirus Disease 2019 (COVID‐19) patients. The ultrasensitive sequential multiplex Simoa assays will enable the simultaneous measurements of multiple low‐abundance analytes in a time‐ and cost‐effective manner and will prove especially critical in many cases where sample volumes are limited.
- 6 September 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (4) , e2001111
Open AccessSequential Protein Capture in Multiplex Single Molecule Arrays: A Strategy for Eliminating Assay Cross‐Reactivity
Measurements of multiple biomolecules within the same biological sample are important for many clinical applications to enable accurate disease diagnosis or classification. These disease‐related biomarkers often exist at very low levels in biological fluids, necessitating ultrasensitive measurement methods. Single‐molecule arrays (Simoa), a bead‐based digital enzyme‐linked immunosorbent assay, is the current state of the art for ultrasensitive protein detection and can detect sub‐femtomolar protein concentrations, but its ability to achieve high‐order multiplexing without cross‐reactivity remains a challenge. Here, a sequential protein capture approach for multiplex Simoa assays is implemented to eliminate cross‐reactivity between binding reagents by sequentially capturing each protein analyte and then incubating each capture bead with only its corresponding detection antibody. This strategy not only reduces cross‐reactivity to background levels and significantly improves measurement accuracies, but also enables higher‐order multiplexing. As a proof of concept, the sequential multiplex Simoa assay is used to measure five different cytokines in plasma samples from Coronavirus Disease 2019 (COVID‐19) patients. The ultrasensitive sequential multiplex Simoa assays will enable the simultaneous measurements of multiple low‐abundance analytes in a time‐ and cost‐effective manner and will prove especially critical in many cases where sample volumes are limited.
- 22 December 2019
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 57 (4) , 270-290
Single-molecule measurements in microwells for clinical applications
The ability to detect and analyze proteins, nucleic acids, and other biomolecules is critical for clinical diagnostics and for understanding the underlying mechanisms of disease. Current detection methods in clinical and research laboratories rely upon bulk measurement techniques such as immunoassays, polymerase chain reaction, and mass spectrometry to detect these biomarkers. However, many potentially useful protein or nucleic acid biomarkers in blood, saliva, or other biofluids exist at concentrations well below the detection limits of current methods, necessitating the development of more sensitive technologies. Single-molecule measurements are poised to address this challenge, vastly improving sensitivity for detecting low abundance biomarkers and rare events within a population. Microwell arrays have emerged as a powerful tool for single-molecule measurements, enabling ultrasensitive detection of disease-relevant biomolecules in easily accessible biofluids. This review discusses the development, fundamentals, and clinical applications of microwell-based single-molecule methods, as well as challenges and future directions for translating these methods to the clinic.
- 22 December 2019
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 57 (4) , 270-290
Single-molecule measurements in microwells for clinical applications
The ability to detect and analyze proteins, nucleic acids, and other biomolecules is critical for clinical diagnostics and for understanding the underlying mechanisms of disease. Current detection methods in clinical and research laboratories rely upon bulk measurement techniques such as immunoassays, polymerase chain reaction, and mass spectrometry to detect these biomarkers. However, many potentially useful protein or nucleic acid biomarkers in blood, saliva, or other biofluids exist at concentrations well below the detection limits of current methods, necessitating the development of more sensitive technologies. Single-molecule measurements are poised to address this challenge, vastly improving sensitivity for detecting low abundance biomarkers and rare events within a population. Microwell arrays have emerged as a powerful tool for single-molecule measurements, enabling ultrasensitive detection of disease-relevant biomolecules in easily accessible biofluids. This review discusses the development, fundamentals, and clinical applications of microwell-based single-molecule methods, as well as challenges and future directions for translating these methods to the clinic.
- 22 February 2019
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 123 (10) , 6090-6096
Characterizing the Incorporation of DNA into Single NIPAm Hydrogel Nanoparticles with Surface Plasmon Resonance Imaging Measurements
- 22 February 2019
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 123 (10) , 6090-6096
Characterizing the Incorporation of DNA into Single NIPAm Hydrogel Nanoparticles with Surface Plasmon Resonance Imaging Measurements
- Open Access
- 10 July 2017
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (7) , 7447-7456
Characterizing Single Polymeric and Protein Nanoparticles with Surface Plasmon Resonance Imaging Measurements
Near-infrared surface plasmon resonance imaging (SPRI) microscopy is used to detect and characterize the adsorption of single polymeric and protein nanoparticles (PPNPs) onto chemically modified gold thin films in real time. The single-nanoparticle SPRI responses, Δ%RNP, from several hundred adsorbed nanoparticles are collected in a single SPRI adsorption measurement. Analysis of Δ%RNP frequency distribution histograms is used to provide information on the size, material content, and interparticle interactions of the PPNPs. Examples include the measurement of log-normal Δ%RNP distributions for mixtures of polystyrene nanoparticles, the quantitation of bioaffinity uptake into and aggregation of porous NIPAm-based (N-isopropylacrylamide) hydrogel nanoparticles specifically engineered to bind peptides and proteins, and the characterization of the negative single-nanoparticle SPRI response and log-normal Δ%RNP distributions obtained for three different types of genetically encoded gas-filled protein nanostructures derived from bacteria.
- 10 July 2017
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (7) , 7447-7456
Open AccessCharacterizing Single Polymeric and Protein Nanoparticles with Surface Plasmon Resonance Imaging Measurements
Near-infrared surface plasmon resonance imaging (SPRI) microscopy is used to detect and characterize the adsorption of single polymeric and protein nanoparticles (PPNPs) onto chemically modified gold thin films in real time. The single-nanoparticle SPRI responses, Δ%RNP, from several hundred adsorbed nanoparticles are collected in a single SPRI adsorption measurement. Analysis of Δ%RNP frequency distribution histograms is used to provide information on the size, material content, and interparticle interactions of the PPNPs. Examples include the measurement of log-normal Δ%RNP distributions for mixtures of polystyrene nanoparticles, the quantitation of bioaffinity uptake into and aggregation of porous NIPAm-based (N-isopropylacrylamide) hydrogel nanoparticles specifically engineered to bind peptides and proteins, and the characterization of the negative single-nanoparticle SPRI response and log-normal Δ%RNP distributions obtained for three different types of genetically encoded gas-filled protein nanostructures derived from bacteria.
- Open Access
- 13 January 2017
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 8 (3) , 576-579
Fabrication of PEDOT Nanocone Arrays with Electrochemically Modulated Broadband Antireflective Properties
Ordered nanocone arrays of the electroactive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) were fabricated by the simultaneous oxygen plasma etching of an electrodeposited PEDOT thin film coated with a hexagonally closed packed polystyrene bead monolayer. PEDOT nanocone arrays with an intercone spacing of 200 nm and an average nanocone height of 350 nm exhibited a low broadband reflectivity of <1.5% from 550 to 800 nm. Electrochemical modulation of the oxidation state of the PEDOT nanocone array film was used to change both its ex situ absorption spectrum (electrochromism) and reflection spectrum (electroreflectivity). The sign of the PEDOT nanocone array electroreflectivity was opposite to that observed from unmodified PEDOT thin films; this significant difference is attributed to the unique optical behavior of nanostructured surfaces with an interfacial layer that contains a graded mix of air and highly absorptive nanocones. The combined electrochromic and electroreflective behavior of the antireflective PEDOT nanocone array films should find promising applications in solar energy cells, sensors and other optical devices.
- 13 January 2017
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 8 (3) , 576-579
Open AccessFabrication of PEDOT Nanocone Arrays with Electrochemically Modulated Broadband Antireflective Properties
Ordered nanocone arrays of the electroactive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) were fabricated by the simultaneous oxygen plasma etching of an electrodeposited PEDOT thin film coated with a hexagonally closed packed polystyrene bead monolayer. PEDOT nanocone arrays with an intercone spacing of 200 nm and an average nanocone height of 350 nm exhibited a low broadband reflectivity of <1.5% from 550 to 800 nm. Electrochemical modulation of the oxidation state of the PEDOT nanocone array film was used to change both its ex situ absorption spectrum (electrochromism) and reflection spectrum (electroreflectivity). The sign of the PEDOT nanocone array electroreflectivity was opposite to that observed from unmodified PEDOT thin films; this significant difference is attributed to the unique optical behavior of nanostructured surfaces with an interfacial layer that contains a graded mix of air and highly absorptive nanocones. The combined electrochromic and electroreflective behavior of the antireflective PEDOT nanocone array films should find promising applications in solar energy cells, sensors and other optical devices.
- 8 November 2016
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 120 (45) , 25958-25966
Surface Plasmon Resonance Imaging Microscopy of Liposomes and Liposome-Encapsulated Gold Nanoparticles
- 8 November 2016
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 120 (45) , 25958-25966
Surface Plasmon Resonance Imaging Microscopy of Liposomes and Liposome-Encapsulated Gold Nanoparticles